Clinical Trial Detail

NCT ID NCT01567930
Title Temsirolimus as Second-line Therapy in HCC
Recruitment Unknown status
Gender both
Phase Phase II
Variant Requirements No
Sponsors University of Tennessee Cancer Institute
Indications

hepatocellular carcinoma

Therapies

Temsirolimus

Age Groups: adult

No variant requirements are available.